Cara Therapeutics' Stock Buoyed By Positive Korsuva Data For Post-Op Pain

 
• By Sten Stovall

Cara Therapeutics will discuss its options with regulators after positive top-line data from adaptive Phase II/III trial of its Korsuva drug in patients undergoing abdominal surgeries met its prime endpoint and sent the biotech's stock higher.

Laparoscopic equipment
Phase II/III Korsuva trial met its primary endpoint in patients undergoing abdominal surgeries • Source: Shutterstock

More from Clinical Trials

More from R&D